Improvements to Nasal Compositions and Method of Use Thereof

Abstract

A nasal composition is provided comprising or consisting of a first composition part in the form of a liquid for nasal application to a patient in use, and a second composition part in the form of a powder for nasal application to the patient in use. The first and second composition parts are applied to the patient separately or together as required.

1 . A nasal composition, said nasal composition comprising or consisting of a first composition part in the form of a liquid for nasal application to a patient in use, and a second composition part in the form of a powder for nasal application to the patient in use, said first and second composition parts applied to the patient separately or together as required. 
     
     
         2 . A nasal composition according to  claim 1  wherein the first liquid composition part includes or consists of any or any combination of one or more therapeutically active agents, a drug, pharmaceutical product, decongestant, allergy therapy agent, herbal agent, homeopathic agent, food supplement, probiotic or airway dilator, and the second powder composition part includes or consists of any or any combination of cellulose powder, hydroxymethylcellulose (HPMC) powder, one or more therapeutically active agents, pharmaceutical agents drug, signalling agents, airway dilator agents, herbal agents, homeopathic agent, probiotics, food supplements, allergy therapy agent, decongestant, or a catalyst and/or an enhancer of a pro-drug contained in the first liquid composition part. 
     
     
         3 . A nasal composition according to  claim 1  wherein the first liquid composition part is applied to the nasal cavity of the patient in the form of a liquid spray or as droplets using a suitable nasal dispenser, and
 the second powder composition is applied to the nasal cavity via nasal inhalation by a patient. 
 
     
     
         4 . (canceled) 
     
     
         5 . (canceled) 
     
     
         6 . A nasal composition according to  claim 2  wherein the therapeutic, homeopathic and/or herbal agent includes one or more of the following properties: antibacterial, antifungal, antiviral, antibiotic, immunomodulating, anti-inflammatory, anti-insomnia, cognitive enhancing or properties that affect cardiovascular function. 
     
     
         7 . A nasal composition according to  claim 2  wherein the therapeutically active agent includes any or any combination of aspirin, isoprenosine, acyclovir, St. John's Wort, valerian extract, ginkgo biloba extract, Vitamins, garlic, lime ginger, ellagic acid, Echinacea, Swedish flower pollen, black walnut hulls, lemongrass, wormwood, grapefruit seed extract, broccoli, digestive enzymes, hyaluronic acid, astralgus, rosehips, gentian, hypericum, horse chesnut, ginseng, green tea, phosphatidyl serine, phosphatidyl choline, citrus, pycnogenol, caffeine, quercitin, co-enzyme Q10, yarrow, tea tree, noni juice, lipase, fructo-oligosaccharide, inulin, black cumin or allicin, any mint variety, turmeric. 
     
     
         8 . A nasal composition according to  claim 1  wherein the second composition part includes a significant proportion of cellulose powder or hydroxymethylcellulose (HPMC) powder therein,
 wherein the second composition part includes at least 50% HPMC or cellulose powder, or 
 wherein the second composition part includes at least 60, 70, 80, 90, 95 or 99% HPMC or cellulose powder by total weight of the second composition part. 
 
     
     
         9 . (canceled) 
     
     
         10 . (canceled) 
     
     
         11 . A nasal composition according to  claim 1  wherein the dosage of the second composition part is between 1 mg-10 mg per nostril of a patient, or
 wherein the dosage of the second composition part is between 2.5 mg-7.5 mg, between 3-7 mg, between 4-6 mg or between 5 mg per nostril of a patient. 
 
     
     
         12 . (canceled) 
     
     
         13 . A nasal composition according to  claim 1  wherein the second composition part includes or consists of cellulose powder or hydroxymethylcellulose (HPMC) powder, and said powder has a viscosity of 10-20 Pa·s in a 2% aqueous solution at 20° C., or
 wherein the powder has a viscosity of 13-17 Pa·s, 14-16 Pa·s or 15 Pa·s. 
 
     
     
         14 . (canceled) 
     
     
         15 . A nasal composition according to  claim 1  wherein the second composition part includes any or any combination of kali bichromium; a thickening agent, gum, starch; a disintegrant, sodium glycolate, a cross linked povidone, a release agent, magnesium stearate; an emulsifying agent, a surfactant, anti-caking agents, granulating agents preservatives or colourant,
 a signalling or flavouring agent that can provide the patient with a pleasant sensory feedback upon use. 
 
     
     
         16 . (canceled) 
     
     
         17 . A nasal composition according to  claim 9  wherein the signalling agent includes any or any combination of mint, menthol, spearmint, any mint variety, turmeric, lemon, lime, peppermint, eucalyptus, strawberry, lavender, citrus or capsaicin. 
     
     
         18 . A nasal composition according to  claim 16  wherein the signalling agent comprises up to 50% of the second composition part, or
 wherein the signalling agent comprises up to 40%, 30%, 20%, 10%, 5%, 2% 1%, 0.5% or 0.25% by total weight of the second composition part. 
 
     
     
         19 . (canceled) 
     
     
         20 . A nasal composition according to  claim 1  wherein the second composition part is administered to the patient prior to or just prior to administration of the first composition part to the patient,
 wherein the first composition part is administered prior to or just prior to administration of the second composition part to the patient, wherein the first composition part and the second composition part are administered simultaneously or substantially simultaneously, or 
 wherein the first composition part and the second composition part, irrespective of the order in which they are administered, are administered sequentially one after another. 
 
     
     
         21 . (canceled) 
     
     
         22 . (canceled) 
     
     
         23 . (canceled) 
     
     
         24 . A nasal composition according to  claim 1  wherein the first and second composition parts are administered less than or equal to 5 minutes after each other, or
 wherein the first and second composition parts are administered less than or equal to 2 minutes after each other less than or equal to 1 minute after each other, less than or equal to 30 seconds after each other, 20 seconds after each other, 10 seconds after each other, 5 seconds after each other or 1 second after each other. 
 
     
     
         25 . (canceled) 
     
     
         26 . A nasal composition according to  claim 1  including or consisting of a third composition part and/or further composition part,
 wherein the first, second, third and/or further composition parts are stand alone, independently applied, composition parts that are not mixed together or come into contact with each other until application into the nasal cavity of a patient. 
 
     
     
         27 . (canceled) 
     
     
         28 . (canceled) 
     
     
         29 . (canceled) 
     
     
         30 . A nasal composition for the manufacture of a medicament for the treatment of a disease relating to the respiratory tract, allergic ailment, rhinitis, the upper respiratory tract and/or the lower respiratory tract of a patient, said nasal composition comprising or consisting of a first composition part in the form of a liquid for nasal application to a patient in use, and a second composition part in the form of a powder for nasal application to the patient in use, said first and second composition parts applied to the patient separately or together as required.